Michael Gelband’s Abeona Therapeutics ABEO Stock Holding History

Michael Gelband’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.31M	Buy	212,325 +89,381	+73%	+$491K	0.01%	985
2026 Q1	$551K	Buy	+122,944	New	+$615K	﹤0.01%	1166
2025 Q2	–	Sell	-24,409	Closed	-$116K	–	1412
2025 Q1	$116K	Buy	+24,409	New	+$133K	﹤0.01%	1338
2023 Q2	–	Sell	-120,853	Closed	-$341K	–	1795
2023 Q1	$341K	Buy	120,853 +26,682	+28%	+$69.7K	﹤0.01%	1439
2022 Q4	$290K	Buy	+94,171	New	+$352K	﹤0.01%	1364
2021 Q4	–	Sell	-663	Closed	-$19K	–	2114
2021 Q3	$19K	Sell	663 -3,424	-84%	-$110K	﹤0.01%	2016
2021 Q2	$159K	Buy	4,087 +3,283	+408%	+$134K	﹤0.01%	2046
2021 Q1	$38K	Buy	+804	New	+$44.3K	﹤0.01%	2042
2019 Q3	–	Sell	-704	Closed	-$84K	–	1298
2019 Q2	$84K	Buy	+704	New	+$118K	﹤0.01%	1034

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OIA

OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Michael Gelband's ABEO Position: Q2 2026 in Review

Michael Gelband increased its Abeona Therapeutics (ABEO) stake by 73% in Q2 2026, buying an estimated $491K and bringing the position to 212,325 shares worth $1.31M. The position accounts for 0.01% of the portfolio, ranked #985.

Michael Gelband first reported a position in ABEO in Q2 2019 and has held it in 9 quarters since. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

Michael Gelband held 212,325 shares of Abeona Therapeutics worth $1.31M as of Q2 2026.
Michael Gelband bought 89,381 Abeona Therapeutics shares in Q2 2026, an estimated $491K.
Abeona Therapeutics made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #985 holding.
Michael Gelband first reported a position in Abeona Therapeutics in Q2 2019 and has held it in 9 quarters since.
126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.